BDX · Insider Trading
Becton, Dickinson and Co.
Every open-market purchase and sale reported by BDX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-27 | Michael Feld | EVP, Chief Revenue Officer | Sell | −76 | −$15.06K |
| 2026-09-29 | Michael Feld | EVP, Chief Revenue Officer | Sell | −76 | −$13.96K |
| 2026-09-03 | Vitor Roque | EVP & Chief Financial Officer | F | −190 | — |
| 2026-08-27 | Michael Feld | EVP, Chief Revenue Officer | Sell | −165 | −$31.10K |
| 2026-08-24 | Michael Feld | EVP, Chief Revenue Officer | F | −1,049 | — |
| 2026-08-14 | Thomas E Polen Jr | Chairman, CEO and President | MIXED | — | −$768.18K |
| 2026-08-12 | Roland Goette | EVP and President, EMEA | Sell | −2,438 | −$440.89K |
| 2026-08-06 | Robert Luther Huffines | Director | A | +189 deriv. | — |
| 2026-08-06 | Carrie L Byington | Director | A | +94 deriv. | — |
| 2026-07-28 | Michael Feld | EVP, Chief Revenue Officer | Sell | −75 | −$11.78K |
| 2026-07-06 | Bilal Muhsin | EVP & President Connected Care | MIXED | +12,407 | — |
| 2026-06-26 | Michael Feld | EVP, Chief Revenue Officer | Sell | −75 | −$11.46K |
| 2026-06-25 | Michael David Garrison | EVP & Pres Med.Essntl&BioPharm | Sell | −1,100 | −$160.23K |
| 2026-06-11 | Michael David Garrison | EVP & Pres Med.Essntl&BioPharm | Sell | −1,100 | −$166.63K |
| 2026-06-03 | Thomas E Polen Jr | Chairman, CEO and President | MIXED | — | −$404.53K |
| 2026-06-02 | Peter Menziuso | EVP and President, BDI | A | +14,258 | — |
| 2026-05-27 | Michael Feld | EVP, Chief Revenue Officer | Sell | −75 | −$11.05K |
| 2026-05-08 | Vitor Roque | EVP & Chief Financial Officer | A | +1,721 | — |
| 2026-05-08 | Carrie L Byington | Director | A | +105 deriv. | — |
| 2026-05-08 | Robert Luther Huffines | Director | A | +210 deriv. | — |
| 2026-04-28 | Michael Feld | EVP, Chief Revenue Officer | Sell | −74 | −$11.24K |
| 2026-04-06 | Shana Carol Neal | EVP and Chief People Officer | F | −1,146 | — |
| 2026-03-27 | Michael Feld | EVP, Chief Revenue Officer | Sell | −75 | −$11.76K |
| 2026-03-17 | Lanesha Minnix | EVP and General Counsel | A | +7,492 | — |
| 2026-03-04 | Pamela L. Spikner | SVP Controller & CAO | A | +931 | — |
| 2026-03-04 | Vitor Roque | Interim CFO | A | +931 | — |
| 2026-02-27 | Michael Feld | EVP, Chief Revenue Officer | Sell | −75 | −$13.64K |
| 2026-02-18 | Bertram L Scott | Director | Sell | −953 | −$174.03K |
| 2026-02-05 | Christopher Ian Montague Jones | Director | A | +272 deriv. | — |
| 2026-02-05 | Carrie L Byington | Director | A | +30 deriv. | — |
| 2026-02-05 | Robert Luther Huffines | Director | A | +100 deriv. | — |
| 2026-01-29 | Jacqueline Wright | Director | A | +1,098 | — |
| 2026-01-29 | Joanne Waldstreicher | Director | A | +1,098 | — |
| 2026-01-29 | Bertram L Scott | Director | A | +1,098 | — |
| 2026-01-29 | Timothy M Ring | Director | A | +1,098 | — |
| 2026-01-29 | Christopher Ian Montague Jones | Director | A | +1,098 | — |
| 2026-01-29 | Robert Luther Huffines | Director | A | +1,098 | — |
| 2026-01-29 | William M Brown | Director | A | +1,098 | — |
| 2026-01-29 | Gregory Hayes | Director | A | +1,098 | — |
| 2026-01-29 | Carrie L Byington | Director | A | +1,098 | — |
| 2026-01-29 | R Andrew Eckert | Director | A | +1,098 | — |
| 2026-01-29 | Jeffrey William Henderson | Director | A | +1,098 | — |
| 2026-01-28 | Michael Feld | EVP, CRO & Pres. Life Sciences | Sell | −75 | −$15.20K |
| 2026-01-23 | Pamela L. Spikner | SVP Controller & CAO | F | −84 | — |
| 2026-01-16 | Michael David Garrison | EVP & Pres Med.Essntl&BioPharm | MIXED | −1,010 | −$334.09K |
| 2026-01-06 | David Shan | EVP and Chief ISC Officer | F | −44 | — |
| 2025-12-29 | Michael Feld | EVP, CRO & Pres. Life Sciences | Sell | −74 | −$14.51K |
| 2025-12-17 | Michael David Garrison | EVP & Pres Med.Essntl&BioPharm | Sell | −629 | −$123.30K |
| 2025-12-02 | Robert Luther Huffines | Director | A | +180 | — |
| 2025-12-02 | Jacqueline Wright | Director | A | +180 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Thomas E Polen Jr | Chairman, CEO and President | 110,163 | $23.37M |
| Timothy M Ring | Director | 61,445 | $13.03M |
| Bilal Muhsin | EVP & President Connected Care | 43,294 | $9.18M |
| Bertram L Scott | Director | 36,763 | $7.80M |
| Christopher DelOrefice | EVP & Chief Financial Officer | 27,227 | $5.78M |
| Christopher Ian Montague Jones | Director | 24,304 | $5.16M |
| Shana Carol Neal | EVP and Chief People Officer | 23,966 | $5.08M |
| Claire Fraser | Director | 22,226 | $4.71M |
| Michael Feld | EVP, Chief Revenue Officer | 19,568 | $4.15M |
| Roland Goette | EVP and President, EMEA | 16,635 | $3.53M |
| Catherine M Burzik | Director | 14,264 | $3.03M |
| Peter Menziuso | EVP and President, BDI | 14,258 | $3.02M |
| Richard Byrd | EVP & President Interventional | 13,183 | $2.80M |
| Michael David Garrison | EVP & Pres Med.Essntl&BioPharm | 13,172 | $2.79M |
| Antoine C Ezell | EVP, President Americas & CMO | 10,708 | $2.27M |
| R Andrew Eckert | Director | 10,423 | $2.21M |
| Jeffrey William Henderson | Director | 9,158 | $1.94M |
| David Shan | EVP and Chief ISC Officer | 8,926 | $1.89M |
| Vitor Roque | EVP & Chief Financial Officer | 8,041 | $1.71M |
| Lanesha Minnix | EVP and General Counsel | 7,492 | $1.59M |
| Michelle Quinn | EVP and General Counsel | 7,303 | $1.55M |
| Gregory Hayes | Director | 7,159 | $1.52M |
| Pavan Kumar Mocherla | EVP & President, Greater Asia | 5,055 | $1.07M |
| Carrie L Byington | Director | 5,018 | $1.06M |
| William M Brown | Director | 4,663 | $989.09K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BDX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.